Japan Keytruda and Opdivo Drug Price Information
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- February 9, 2017
- Read time: 1 minute
Last year, we shared with everyone that Japan's Ministry of Health, Labour and Welfare's Central Social Insurance Medical Council had been conducting a series of discussions on drug pricing — among which the two immune checkpoint inhibitor drugs Keytruda and Opdivo were mentioned. At the 345th Central Social Insurance Medical Council meeting yesterday, price revisions were announced.
Keytruda: 20 mg — ¥84,488; 100 mg — ¥410,541. Opdivo, also a PD-1 inhibitor: 20 mg — ¥75,100; 100 mg — ¥364,925.
The approved indications for both of these immunotherapy drugs include melanoma and PD-L1-positive unresectable non-small cell lung cancer. For dosing information, please consult your attending physician or refer to the official websites of MSD (Merck) or Ono Pharmaceutical.
Source: Central Social Insurance Medical Council General Meeting (345th Session), February 8, 2017 (Wednesday), 9:00 AM, Ministry of Health, Labour and Welfare Auditorium (Low-rise Building, 2nd Floor)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5